Cargando…
The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer
The present study aims to evaluate the pretherapeutic Fibrinogen-Albumin-Ratio Index (FARI), as currently reliable biomarkers to predict therapy response and prognosis of patients with advanced vulvar cancer are missing. Data of 124 consecutive patients, who underwent primary resection for vulvar ca...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694316/ https://www.ncbi.nlm.nih.gov/pubmed/36579608 http://dx.doi.org/10.3390/jpm12111882 |
_version_ | 1784837769882763264 |
---|---|
author | Onoprienko, Arina Hofstetter, Gerda Dorittke, Tim Bekos, Christine Grimm, Christoph Polterauer, Mariella Bartl, Thomas Polterauer, Stephan |
author_facet | Onoprienko, Arina Hofstetter, Gerda Dorittke, Tim Bekos, Christine Grimm, Christoph Polterauer, Mariella Bartl, Thomas Polterauer, Stephan |
author_sort | Onoprienko, Arina |
collection | PubMed |
description | The present study aims to evaluate the pretherapeutic Fibrinogen-Albumin-Ratio Index (FARI), as currently reliable biomarkers to predict therapy response and prognosis of patients with advanced vulvar cancer are missing. Data of 124 consecutive patients, who underwent primary resection for vulvar cancer ≥ pT1b, were retrospectively analyzed. Associations between the FARI and disease recurrence were assessed fitting receiver operating characteristics (ROC) and binary logistic regression models; univariate and multivariable Cox regression models for disease-specific survival (DSS) and progression-free survival (PFS) were performed. A pretherapeutic low FARI cut at its median (<9.67) is significantly associated with younger age (65.5 vs. 74.0 years) and higher risk of recurrence (52.4% vs. 26.2%). The ROC analysis calculates the area under the curve (AUC) of the FARI for a PFS < 6 months of 0.700 and for a DSS < 12 months of 0.706, outperforming fibrinogen and albumin alone. The FARI remained independently predictive for PFS (HR 0.84, 95% CI [0.99–1.03], p = 0.009) and DSS (HR 0.82, 95% CI [0.70–0.99], p = 0.019), also in multivariable survival analysis. Despite the FARI’s promising predictive and prognostic value, however, further elucidation of its precise mode of action is warranted before clinical application as it appears to rely only on subtle changes of fibrinogen levels. |
format | Online Article Text |
id | pubmed-9694316 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96943162022-11-26 The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer Onoprienko, Arina Hofstetter, Gerda Dorittke, Tim Bekos, Christine Grimm, Christoph Polterauer, Mariella Bartl, Thomas Polterauer, Stephan J Pers Med Article The present study aims to evaluate the pretherapeutic Fibrinogen-Albumin-Ratio Index (FARI), as currently reliable biomarkers to predict therapy response and prognosis of patients with advanced vulvar cancer are missing. Data of 124 consecutive patients, who underwent primary resection for vulvar cancer ≥ pT1b, were retrospectively analyzed. Associations between the FARI and disease recurrence were assessed fitting receiver operating characteristics (ROC) and binary logistic regression models; univariate and multivariable Cox regression models for disease-specific survival (DSS) and progression-free survival (PFS) were performed. A pretherapeutic low FARI cut at its median (<9.67) is significantly associated with younger age (65.5 vs. 74.0 years) and higher risk of recurrence (52.4% vs. 26.2%). The ROC analysis calculates the area under the curve (AUC) of the FARI for a PFS < 6 months of 0.700 and for a DSS < 12 months of 0.706, outperforming fibrinogen and albumin alone. The FARI remained independently predictive for PFS (HR 0.84, 95% CI [0.99–1.03], p = 0.009) and DSS (HR 0.82, 95% CI [0.70–0.99], p = 0.019), also in multivariable survival analysis. Despite the FARI’s promising predictive and prognostic value, however, further elucidation of its precise mode of action is warranted before clinical application as it appears to rely only on subtle changes of fibrinogen levels. MDPI 2022-11-10 /pmc/articles/PMC9694316/ /pubmed/36579608 http://dx.doi.org/10.3390/jpm12111882 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Onoprienko, Arina Hofstetter, Gerda Dorittke, Tim Bekos, Christine Grimm, Christoph Polterauer, Mariella Bartl, Thomas Polterauer, Stephan The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer |
title | The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer |
title_full | The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer |
title_fullStr | The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer |
title_full_unstemmed | The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer |
title_short | The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer |
title_sort | prognostic value of the fibrinogen-albumin-ratio index (fari) in patients with advanced vulvar cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694316/ https://www.ncbi.nlm.nih.gov/pubmed/36579608 http://dx.doi.org/10.3390/jpm12111882 |
work_keys_str_mv | AT onoprienkoarina theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT hofstettergerda theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT dorittketim theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT bekoschristine theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT grimmchristoph theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT polterauermariella theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT bartlthomas theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT polterauerstephan theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT onoprienkoarina prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT hofstettergerda prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT dorittketim prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT bekoschristine prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT grimmchristoph prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT polterauermariella prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT bartlthomas prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer AT polterauerstephan prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer |